Pasithea Therapeutics (KTTA) announced positive interim pharmacodynamic data from its ongoing Phase 1 trial of PAS-004 in advanced cancer patients. The data includes results from cohorts 3 and 4A, evaluating 8mg and 15mg capsules, as well as cohort 4B evaluating 4mg tablets, and demonstrates strong target engagement consistent with PAS-004’s favorable pharmacological profile. Inhibition of ERK phosphorylation, pERK, is widely recognized as a gold-standard PD biomarker for assessing MEK inhibitor activity. To evaluate target engagement, pERK levels were measured in peripheral blood mononuclear cells collected from patients at baseline and steady-state at day 22. Preliminary results demonstrate robust pERK inhibition, with reductions in pERK levels of up to 91% even at the 8mg dose level, in line with a previous developed PK/PD model, confirming substantial target engagement in patients receiving PAS-004.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KTTA:
- Pasithea Therapeutics files to sell 3.25M shares of common stock, warrants
- Pasithea completes enrollment in cohort 6 of Phase 1 trial of PAS-004
- Pasithea Therapeutics to present updated data from Phase 1 trial of PAS-004
- Morning Movers: Capri Holdings jumps following sale of Versace to Prada
- Pasithea says SRC recommends Phase 1 PAS-004 trial escalate to next dose level